# DAREON-7 (NCT06132113)

> DAREON™-7: A Study to Test How Well Different Doses of BI 764532 in Addition to Chemotherapy Are Tolerated by People With Advanced Neuroendocrine Cancers

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT06132113
- Phase: PHASE1
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Boehringer Ingelheim
- Conditions: Neuroendocrine Neoplasms
- Interventions: BI 764532; Carboplatin; Etoposide; Cisplatin
- Enrollment: 65
- Primary outcome: Part A1: Occurrence of dose-limiting toxicities (DLTs) in the maximum tolerated dose (MTD) evaluation period
- Primary outcome: Part B: Occurrence of dose-limiting toxicities (DLTs) during the on-treatment period
- Primary outcome: Part A2: Reduced monitoring: the occurrence of DLTs during the on-treatment period

## Indexed commentary on DAREON-7 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 12
- YouTube: 5
- Podcasts: 1

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=dareon-7-nct06132113

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT06132113", "email": "<work email>"}; the inbox owner confirms by the emailed link.